Beijing, China, the morning of 30 August, 2023-The initiation meeting of the Phase I/II clinical study of [¹⁷⁷Lu]Lu-XT033 Injection initiated by Sinotau was successfully held at Beijing Cancer Hospital. This clinical study is to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic profile, and efficacy of [¹⁷⁷Lu]Lu-XT033 Injection in patients with metastatic prostate cancer.

Director Zhi Yang , Prof. Hua Zhu, Prof. Feng Wang, Dr.Chen Liu and nursing team from Department of Nuclear Medicine, Peking University Cancer Hospital, and Dr. Yongpeng Ji, clinician and nursing team from Department of Urology attended the launch meeting. Ms. Yan Zhang, Head of Medicine and Ms. Xiangjun Zheng, Head of Clinical Operations of Sinotau attended the meeting together with relevant personnel of the company.

▲Kick-off meeting was successfully held at Peking University Cancer Hospital

At the meeting site, the representative of Sinotau sent sincere thanks to the attending guests. The medical manager of this project made a detailed introduction of the clinical trial program, and the representatives of the attending clinical experts put forward suggestions on the quantification of the entry criteria and the precautions for enrollment from a professional point of view, and held discussions around the quality management of the clinical trial program.

As the first unit to hold the project kick-off meeting, Beijing Cancer Hospital will soon enroll the first participant, with the research teams from the departments of Nuclear Medicine and Urology working together to advance the clinical study of [¹⁷⁷Lu]Lu-XT033 injection.

Let us look forward to the smooth implementation of the [¹⁷⁷Lu]Lu-XT033 injection project, and bring new treatment options to patients with metastatic castration-resistant prostate cancer as soon as possible!